insulin LISPRO (Humalog)

Subscribe to Selected New Research on insulin LISPRO

203 relevant articles (33 outcomes, 41 trials/studies) found for this Drug

Description: a recombinant DNA human insulin analog; first SY's for human form; amino acid sequences of ox and human forms in first source

Also Known As:

Humalog; LYSPRO; 28(B)-Lys-29(B)-Pro-insulin; 28(B)-lysine-29(B)-prolineinsulin; B28-Lys-B29-Pro-insulin; insulin, Lys(28B)-Pro(29B)-; insulin, Lys(B28)-Pro(B29); insulin, lysine(B28)-proline(B29); insulin, lysyl(28B)-prolyl(28B)-; lispro

Relationship Network

Drug Context: Research Results

Hormones, Hormone Substitutes, and Hormone Antagonists

Hormones: 44075

Peptide Hormones: 371

Pancreatic Hormones: 78

Proinsulin: 619

Insulin: 54407

insulin LISPRO: 203

Amino Acids, Peptides, and Proteins

Peptides: 16074

Peptide Hormones: 371

Pancreatic Hormones: 78

Proinsulin: 619

Insulin: 54407

insulin LISPRO: 203

Experts

1.	Johansson, U B: 2 articles (12/2007 - 05/2000)
2.	Lins, P E: 2 articles (12/2007 - 05/2000)
3.	Arora, V: 2 articles (09/2003 - 02/2000)
4.	Campaigne, B N: 2 articles (09/2003 - 02/2000)
5.	Nakagawa, Koichi: 1 article (09/2008)
6.	Tone, Atsuhito: 1 article (09/2008)
7.	Makino, Hirofumi: 1 article (09/2008)
8.	Shikata, Kenichi: 1 article (09/2008)
9.	Hashimoto, Masaaki: 1 article (09/2008)
10.	Esposito, K: 1 article (01/2008)

Related Diseases

1.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 05/01/1999 - "Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus." 08/01/1997 - "Strategies toward improved control during insulin lispro therapy in IDDM" 03/01/1997 - "Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus." 11/01/2002 - "Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus." 01/01/1998 - "In order to assess the therapeutical value of lispro, we have had an open-label, non-comparative study, for 12 weeks, involving 19 IDDM patients" Get all the results and reference details, order at left...
2.	Hypoglycemia (Reactive Hypoglycemia) 07/01/2001 - "OBJECTIVE: To assess the potential of insulin lispro to limit the frequency of severe hypoglycaemia without compromising glycaemic control in a cohort of patients with type 1 diabetes who are at a high risk of severe hypoglycemia" 05/01/2000 - "In conclusion our case report suggests that IP tends to reduce the average glycemia and affect the amplitude of glycemic fluctuations in comparison with CSII using lispro, with an equivalent risk for severe hypoglycemia" 03/01/1999 - "Intensive therapy with lispro + NPH results in less frequent hypoglycemia and better awareness and counterregulation of hypoglycemia." 10/01/1998 - "Early preprandial hypoglycemia after administration of insulin lispro." 10/01/1998 - "Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes." Get all the results and reference details, order at left...
3.	Type 2 Diabetes Mellitus (MODY) 10/01/1999 - "This study assessed the safety profile and efficacy of a new combination therapy (insulin lispro plus sulfonylurea) in patients with type 2 diabetes mellitus experiencing secondary oral agent failure" 02/01/2000 - "Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus." 06/09/1997 - "The efficacy of insulin lispro in the clinical therapy of patients with non-insulin-dependent diabetes mellitus (NIDDM) has not been tested" 01/01/2008 - "Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus." 09/01/2003 - "Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus." Get all the results and reference details, order at left...
4.	Hyperglycemia 03/01/2008 - "These findings suggest that insulin lispro could be useful for the treatment of hyperglycemia in type 1 diabetic pregnant women." 05/01/2005 - "In women with gestational diabetes mellitus (GDM), the use of insulin lispro is efficient in reducing postprandial hyperglycemia and some neonatal features related to hyperglycemia, thus stressing its usefulness in this condition" 01/01/1999 - "RESEARCH DESIGN AND METHODS: In 48 randomized overnight studies, 12 healthy adult type 1 diabetic patients received lispro insulin 0.15 U/kg admixed with human ultralente 0.2 U/kg (as background insulin) subcutaneously at minutes (-30, -15, 0, and +15) relative to the ingestion of an American Diabetes Association breakfast of 8.6 kcal/kg. Pre-breakfast hyperglycemia of 10.2 +/- 0.2 mmol/l was established before the study by continuous overnight infusion of intravenous insulin, which was stopped 30 min before lispro insulin injection" 12/01/1996 - "CONCLUSIONS: The more rapid action of lispro is an advantage in the correction of hyperglycemia, even though actual differences in glucose concentrations are smaller than suggested by previous clamped studies." 02/01/2006 - "Lispro reduced postprandial hyperglycemia and total glucose area under the curve" Get all the results and reference details, order at left...
5.	Diabetes Mellitus 01/01/1998 - "Safety and efficacy of insulin lispro in patients with diabetes mellitus." 01/01/1997 - "We examined the safety and efficacy of insulin lispro in the premeal treatment of patients with diabetes mellitus" 11/01/1996 - "A few of the studies used patients with diabetes mellitus in multicenter, randomized, crossover trials of insulin lispro" 11/01/1996 - "STUDY SELECTION: Due to the relatively few citations listed in MEDLINE (12 as of December 1995), most of the studies reported were found from abstracts summarizing the clinical action, adverse effects, or pharmacokinetics of insulin lispro in healthy volunteers or patients with diabetes mellitus" 06/01/2008 - "AIM: To determine the rate of major congenital anomalies and complications retrospectively in offspring of women with diabetes mellitus treated insulin lispro" Get all the results and reference details, order at left...
55 Diseases and 203 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Asp(B28)- insulin (NovoLog)
3.	Glucose (Dextrose)
4.	basal insulin
5.	Blood Glucose (Blood Sugar)
6.	glargine (insulin glargine)
7.	Isophane Insulin (NPH Insulin)
8.	Heparin (Liquaemin)
9.	Insulin Antibodies
10.	Glyburide (Glibenclamide)
56 Drugs and Important Bio-Agents and 179 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Therapeutics
2.	Metered Dose Inhalers (Metered Dose Inhaler)
3.	Intensive Care (Surgical Intensive Care)
4.	Nebulizers and Vaporizers (Inhaler)
5.	Renal Dialysis (Hemodialysis)
5 Therapies and Procedures and 4 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>